📊 ARGX Key Takeaways
Is Argenx SE (ARGX) a Good Investment?
Insufficient financial data available for fundamental analysis. All key income statement, balance sheet, cash flow, and profitability metrics are unavailable, preventing assessment of financial health, operational performance, or growth quality.
argenx’s fundamentals have improved sharply as VYVGART/VYVGART SC scaled from $876 million of first-half 2024 net sales to $1.739 billion in first-half 2025, driving a swing from operating loss to $340 million of operating profit and from negative to positive operating cash flow. The balance sheet is exceptionally strong, with about $3.9 billion of cash plus current financial assets and low liabilities, giving the company ample capacity to fund pipeline expansion. Growth quality is strong, but the story still depends heavily on one franchise and continued execution across new indications.
Why Buy Argenx SE Stock? ARGX Key Strengths
- Operates in biopharmaceutical sector with potential for high-value therapeutics
- Listed on major exchange (Nasdaq) indicating regulatory compliance
- CIK registration confirms SEC reporting company status
- Explosive revenue growth with first-half 2025 product net sales up about 98% year over year
- Clear operating leverage as first-half 2025 operating profit reached $340 million versus a $139 million loss a year earlier
- Very strong financial position with roughly $2.1 billion cash, $1.8 billion current financial assets, and total equity far exceeding liabilities
ARGX Stock Risks: Argenx SE Investment Risks
- Complete absence of revenue and profitability data prevents financial viability assessment
- No balance sheet data available to evaluate liquidity or solvency
- Zero insider transactions in last 90 days combined with data gaps raises data quality concerns
- Inability to assess cash burn rate, R&D efficiency, or runway for pre-commercial biotech
- Revenue is highly concentrated in the VYVGART franchise, increasing product and indication concentration risk
- Expense base remains heavy as R&D and commercialization spending continue to rise alongside pipeline expansion
- Reported 2024 net income was helped by a large tax benefit, so durable earnings quality is better judged on 2025 operating and cash flow performance
Key Metrics to Watch
- Revenue recognition and product commercialization milestones
- Cash position and quarterly burn rate
- Operating expenses relative to available capital
- VYVGART/VYVGART SC product net sales growth by indication and geography
- Operating cash flow and operating margin as pipeline and commercial spending scale
Argenx SE (ARGX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ARGX Profit Margin, ROE & Profitability Analysis
ARGX vs Healthcare Sector: How Argenx SE Compares
How Argenx SE compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Argenx SE Stock Overvalued? ARGX Valuation Analysis 2026
Based on fundamental analysis, Argenx SE has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Argenx SE Balance Sheet: ARGX Debt, Cash & Liquidity
ARGX Revenue Growth, EPS Growth & YoY Performance
ARGX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Argenx SE (CIK: 0001697862)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ARGX
What is the AI rating for ARGX?
Argenx SE (ARGX) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 50% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ARGX's key strengths?
Claude: Operates in biopharmaceutical sector with potential for high-value therapeutics. Listed on major exchange (Nasdaq) indicating regulatory compliance. ChatGPT: Explosive revenue growth with first-half 2025 product net sales up about 98% year over year. Clear operating leverage as first-half 2025 operating profit reached $340 million versus a $139 million loss a year earlier.
What are the risks of investing in ARGX?
Claude: Complete absence of revenue and profitability data prevents financial viability assessment. No balance sheet data available to evaluate liquidity or solvency. ChatGPT: Revenue is highly concentrated in the VYVGART franchise, increasing product and indication concentration risk. Expense base remains heavy as R&D and commercialization spending continue to rise alongside pipeline expansion.
What is ARGX's revenue and growth?
Argenx SE reported revenue of N/A.
Does ARGX pay dividends?
Argenx SE does not currently pay dividends.
Where can I find ARGX SEC filings?
Official SEC filings for Argenx SE (CIK: 0001697862) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ARGX's EPS?
Argenx SE has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ARGX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Argenx SE has a BUY rating with 50% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is ARGX stock overvalued or undervalued?
Valuation metrics for ARGX: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ARGX stock in 2026?
Our dual AI analysis gives Argenx SE a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ARGX's free cash flow?
Argenx SE's operating cash flow is N/A, with capital expenditures of N/A.
How does ARGX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).